 2. Has a history or presence of clinically significant CS cardiovascular, pulmonary, hepatic, gallbladder or biliary tract, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease, which in the Investigators opinion would not be suitable for the study from patient safety consideration and could interfere the results of the trial. 